Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Clip: Is the world more dangerous after the Iran war? Iran appears to be significantly degraded as a military power, but its agreement with the U.S. could open new revenue streams for the regime. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results